FDA To Consider Behind-The-Counter Drugs

Law360, New York (October 4, 2007, 12:00 AM EDT) -- The U.S. Food and Drug Administration announced on Thursday that it will consider offering a third class of drugs, sold from behind pharmacy counters, in addition to traditional prescription and over-the-counter drugs.

In a notice printed in Thursday’s issue of the U.S. Federal Register, the FDA announced that it would hold a public meeting on Nov. 14 on so-called behind-the-counter drugs.

“The FDA is interested in obtaining public comment as it explores the public health benefit of certain drugs being available without a prescription but only...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.